MedTrace Logo

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

NCT04746924 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 669

Last updated 2026-05-12

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy and safety of ociperlimab + tislelizumab compared with that of pembrolizumab in adults with high levels of programmed cell death ligand-1 (PD-L1), locally advanced/recurrent or untreated metastatic non-small cell lung cancer (NSCLC).

Conditions

Interventions

DRUG

Tislelizumab

Tislelizumab is a monoclonal antibody formulated for intravenous injection.

DRUG

Ociperlimab

Ociperlimab is a monoclonal antibody formulated for intravenous injection.

DRUG

Pembrolizumab

Pembrolizumab is a monoclonal antibody formulated for intravenous injection.

DRUG

Placebo

Placebo infusions will consist of a sterile, normal saline solution.

Sponsors & Collaborators

  • BeiGene

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-24
Primary Completion
2025-05-30
Completion
2026-03-18
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Australia
  • Brazil
  • China
  • France
  • Georgia
  • Germany
  • Italy
  • Japan
  • Netherlands
  • Poland
  • Russia
  • South Korea
  • Spain
  • Taiwan
  • Thailand
  • Turkey (Türkiye)
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04746924 on ClinicalTrials.gov